Welcome to Kristin Davis, MSc, our new Project Manager, Scientific Affairs at CQDM! Kristin joined us in, bringing over five years of experience in research funding, both in grant administration and from the recipient’s perspective. She has successfully managed complex, interdisciplinary projects in public health, molecular biology, and psychiatry. With a BSc in Biochemistry from…
This partnership was made possible through a CQDM Connect-Pharma call for proposals, an initiative that gives Canadian companies and researchers the opportunity to directly engage with CQDM’s international pharmaceutical members.CQDM plays a unique role as a facilitator of healthcare innovation, going well beyond financial investment. Thanks to its strong connections with major pharmaceutical players and…
Congratulations to Synucure Therapeutics, which has just completed a $2.8 million financing round, with 50% of the funding coming from the Government of Québec through Investissement Québec as part of the Impulsion PME program.👏CQDM is proud to have supported this project by acting as an advisor and referring entity, helping facilitate access to this crucial…
Announcement Montreal, March 12, 2025 – The CQDM Board of Directors is proud to announce the appointment of Véronique Dugas as the next President and Chief Executive Officer (CEO) of CQDM. She will succeed Diane Gosselin, who, after 17 years of dedicated service to the organization, including 13 years at its helm, will be retiring.…
🚀💊 Are you ready to revolutionize the digital health and artificial intelligence (AI) sectors? Join the Merck Digital Sciences Studio (MDSS) and collaborate with a global leader! 🧬🔍 The MDSS program in partnership with Centech Mtl and CQDM is a six-month program in Montreal that equips startups in the digital health and AI sectors with…
Montreal, February 21, 2025 – CQDM is pleased to announce the funding of a collaborative research project aimed at developing new tumor-specific therapeutic candidates designed to minimize toxicities and side effects of oncology therapies, using an innovative approach based on artificial intelligence (AI). This project, worth a total of $2,056,964, is being carried out jointly…
Connect-BIO: New Opportunities Brought by Artificial Intelligence in the Development of Advanced Therapies The CQDM invites you to its must-attend event, Connect-BIO, a gathering for researchers and entrepreneurs passionate about artificial intelligence and its impact on the development of advanced therapies. What to Expect: 📅 Date: February 20, 2025🕔 Time: 4:30 PM to 7:30 PM📍…
Announcement OTTAWA, Ontario – Jan. 9, 2025 – Esphera SynBio, a pre-clinical stage synthetic biology company, today announced a new project aimed at advancing next-generation mRNA vaccines. Using its proprietary technology, Esphera SynBio causes the production of modified nanomedicines within patients upon delivery of LNP/mRNA vaccines. These in situ produced nanomedicines can have precise targeting…
Welcome to Lina Chaya, our new Administration Coordinator! With a Master’s degree in Administration and a specialization in Public Management from ÉNAP, she brings extensive administrative experience gained in both public and private organizations, in Quebec and Lebanon.Lina has notably held various roles in analysis, management, and coordination at Desjardins, CNESST, and HEC Montréal. 🌟…
Call for Ideas: AI-assisted protein design CQDM is pleased to launch a call for ideas for our upcoming CQDM Connect-Pharma: Pitch Day. We are searching for world-class research on AI-assisted protein design to present to domain experts from leading global pharmaceutical organizations on March 5, 2025.Our objective is to bring ground-breaking, innovative Canadian research to…